GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Degree of Financial Leverage

Greenwich LifeSciences (Greenwich LifeSciences) Degree of Financial Leverage : 0.89 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Greenwich LifeSciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.89. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Greenwich LifeSciences's Degree of Financial Leverage or its related term are showing as below:

GLSI's Degree of Financial Leverage is ranked better than
54.76% of 1501 companies
in the Biotechnology industry
Industry Median: 0.96 vs GLSI: 0.89

Greenwich LifeSciences Degree of Financial Leverage Historical Data

The historical data trend for Greenwich LifeSciences's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Degree of Financial Leverage Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial 1.00 1.05 0.95 0.93 0.92

Greenwich LifeSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.96 0.99 0.92 0.89

Competitive Comparison of Greenwich LifeSciences's Degree of Financial Leverage

For the Biotechnology subindustry, Greenwich LifeSciences's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Degree of Financial Leverage falls into.



Greenwich LifeSciences Degree of Financial Leverage Calculation

Greenwich LifeSciences's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.72 (Mar. 2024) / -0.63 (Mar. 2023) - 1 )/( -9.624 (Mar. 2024) / -8.292 (Mar. 2023) - 1 )
=0.1429/0.1606
=0.89***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Greenwich LifeSciences  (NAS:GLSI) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Greenwich LifeSciences Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530

Greenwich LifeSciences (Greenwich LifeSciences) Headlines

From GuruFocus

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

By Business Wire Business Wire 07-11-2022

Could Insider Buying Signal that Greenwich LifeSciences Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 02-14-2023

Is Greenwich LifeSciences Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 05-19-2023